{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:30Z","timestamp":1792784610300,"version":"4.5.0"},"reference-count":43,"publisher":"American Chemical Society (ACS)","issue":"19","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2022CXPT038"],"award-info":[{"award-number":["2022CXPT038"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Qingdao Key Technology Research and Industrialization Demonstration Projects","award":["24-1-4-xxgg-15-nsh"],"award-info":[{"award-number":["24-1-4-xxgg-15-nsh"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic cancer driven by the KRASG12D mutation faces therapeutic challenges from KRAS undruggability and acquired resistance to inhibitors like MRTX1133 via secondary mutations (e.g., Q95\/Y96). Here, we report ZJK-807, a novel cereblon (CRBN)-based proteolysis-targeting chimera (PROTAC), conjugating a KRASG12D inhibitor to a CRBN ligand. It selectively degrades KRASG12D (DC50 = 79.5 \u00b1 5.4 nM in AsPC-1 cells) with minimal impact on wild-type KRAS or other mutants (G12C\/S\/V, G13D), inducing mutant-specific cytotoxicity. Critically, ZJK-807 overcomes secondary mutation resistance by degrading mutant KRASG12D and suppressing resistant cell growth where MRTX1133 fails. Transcriptomic analysis revealed that ZJK-807 suppresses RAS\/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis, suggesting distinct mechanistic advantages. In vivo, ZJK-807 (30 mg\/kg, subcutaneous) achieved 47% tumor growth inhibition in AsPC-1 xenografts with favorable pharmacokinetics. This study presents a CRBN-based PROTAC to selectively target and degrade resistant KRASG12D mutants, establishing a groundbreaking approach for KRAS-driven malignancies.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c01034","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T22:22:47Z","timestamp":1758838967000},"page":"20103-20129","source":"Crossref","is-referenced-by-count":12,"title":["ZJK-807: A Selective\nPROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic\nCancer"],"prefix":"10.1021","volume":"68","author":[{"given":"Zhaojuan","family":"Liu","sequence":"first","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heping","family":"Zheng","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Tian","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyue","family":"Li","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Marine Biomedical Research Institute of Qingdao , , ,","place":["Qingdao, Shandong, China, 266071"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Marine Biomedical Research Institute of Qingdao , , ,","place":["Qingdao, Shandong, China, 266071"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-1683","authenticated-orcid":true,"given":"Siqi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Ma","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Marine Biomedical Research Institute of Qingdao , , ,","place":["Qingdao, Shandong, China, 266071"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7364-2459","authenticated-orcid":true,"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Marine Biomedical Research Institute of Qingdao , , ,","place":["Qingdao, Shandong, China, 266071"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8108-1698","authenticated-orcid":true,"given":"Chong","family":"Qin","sequence":"additional","affiliation":[{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Qingdao Marine Science and Technology Center , , , ,","place":["Qingdao, Shandong, China, 266137"]},{"name":"Ocean University of China , , , ,","place":["Qingdao, Shandong, China, 266003"]},{"name":"Marine Biomedical Research Institute of Qingdao , , ,","place":["Qingdao, Shandong, China, 266071"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"1","key":"2026072715454438100_cit1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS Mutation: From Undruggable to\nDruggable in Cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target.\nTher"},{"issue":"10","key":"2026072715454438100_cit2","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A Comprehensive\nSurvey of Ras Mutations\nin Cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res."},{"issue":"7","key":"2026072715454438100_cit3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/s41417-024-00778-4","article-title":"Targeting\nKRASG12D Mutation in Non-Small Cell Lung Cancer: Molecular Mechanisms\nand Therapeutic Potential","volume":"31","author":"Tang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"2026072715454438100_cit4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.sbi.2021.06.013","article-title":"Stopping the Beating\nHeart of Cancer: KRAS Reviewed","volume":"71","author":"Herdeis","year":"2021","journal-title":"Curr. Opin.\nStruct. Biol."},{"issue":"11","key":"2026072715454438100_cit5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging\nthe Undruggable RAS: Mission Possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat.\nRev. Drug Discovery"},{"issue":"1","key":"2026072715454438100_cit6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12943-019-1012-4","article-title":"Small Molecule\nKRAS Agonist for Mutant KRAS Cancer Therapy","volume":"18","author":"Xu","year":"2019","journal-title":"Mol. Cancer"},{"issue":"9","key":"2026072715454438100_cit7","doi-asserted-by":"publisher","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: The Critical\nDriver and Therapeutic Target for\nPancreatic Cancer","volume":"8","author":"Waters","year":"2018","journal-title":"Cold Spring Harb. Perspect.\nMed."},{"issue":"1","key":"2026072715454438100_cit8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins\nand Their Regulators\nin Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"6","key":"2026072715454438100_cit9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamaoncol.2016.0405","article-title":"Prognostic and Predictive\nValue in KRAS in Non\u2013Small-Cell Lung Cancer:\nA Review","volume":"2","author":"Wood","year":"2016","journal-title":"JAMA Oncol"},{"issue":"11","key":"2026072715454438100_cit10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct Small-Molecule Inhibitors\nof KRAS: From Structural\nInsights to Mechanism-Based Design","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat. Rev.\nDrug Discovery"},{"issue":"7781","key":"2026072715454438100_cit11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The Clinical KRAS(G12C)\nInhibitor AMG 510 Drives Anti-Tumour Immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2026072715454438100_cit12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C\nInhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility\nof KRAS-Mutant Cancers in Mouse Models and Patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discovery"},{"issue":"23","key":"2026072715454438100_cit13","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-Human Phase I\/IB Dose-Finding\nStudy of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin.\nOncol."},{"issue":"10","key":"2026072715454438100_cit14","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-Tumor Efficacy of a Potent and\nSelective Non-Covalent KRASG12D Inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat.\nMed."},{"issue":"4","key":"2026072715454438100_cit15","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of\nMRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026072715454438100_cit16","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-Tumor Efficacy\nof HRS-4642 and Its Potential Combination with Proteasome Inhibition\nin KRAS G12D-Mutant Cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"issue":"Suppl_7","key":"2026072715454438100_cit17","doi-asserted-by":"publisher","first-page":"ND03","DOI":"10.1158\/1538-7445.am2024-nd03","article-title":"Abstract ND03: Discovery\nof RMC-9805, an Oral, Covalent Tri-Complex KRASG12D(ON) Inhibitor","volume":"84","author":"Knox","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"2026072715454438100_cit18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","article-title":"KRAS(G12D) Can Be Targeted\nby Potent Inhibitors via Formation of\nSalt Bridge","volume":"8","author":"Mao","year":"2022","journal-title":"Cell Discovery"},{"issue":"7968","key":"2026072715454438100_cit19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS Inhibitor Disables Oncogenic\nSignalling and Tumour Growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"2026072715454438100_cit20","volume-title":"A Phase 1\/2 Multiple\nExpansion Cohort Trial\nof MRTX1133 in Patients with Advanced Solid Tumors Harboring a KRAS\nG12D Mutation; Clinical Trial Registration NCT05737706","author":"Mirati Therapeutics Inc.","year":"2025"},{"key":"2026072715454438100_cit21","doi-asserted-by":"publisher","first-page":"S1273","DOI":"10.1016\/j.annonc.2023.10.025","article-title":"LBA33 A First-in-Human\nPhase I Study of a Novel KRAS\nG12D Inhibitor HRS-4642 in Patients with Advanced Solid Tumors Harboring\nKRAS G12D Mutation","volume":"34","author":"Zhou","year":"2023","journal-title":"Ann. Oncol."},{"issue":"Suppl_4","key":"2026072715454438100_cit22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1200\/jco.2025.43.4_suppl.724","article-title":"Preliminary Safety, Antitumor Activity, and Circulating\nTumor DNA (ctDNA) Changes with RMC-9805, an Oral, RAS(ON) G12D-Selective\nTri-Complex Inhibitor in Patients with KRAS G12D Pancreatic Ductal\nAdenocarcinoma (PDAC) from a Phase 1 Study in Advanced Solid Tumors","volume":"43","author":"Spira","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026072715454438100_cit23","doi-asserted-by":"publisher","first-page":"216904","DOI":"10.1016\/j.canlet.2024.216904","article-title":"Site-Specific Mutagenesis Screening\nin KRAS Mutant Library to Uncover Resistance Mechanisms to KRASG12D\nInhibitors","volume":"591","author":"Choi","year":"2024","journal-title":"Cancer Lett."},{"issue":"17","key":"2026072715454438100_cit24","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1158\/0008-5472.CAN-23-0592","article-title":"A Nonconserved\nHistidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D\nInhibitor MRTX1133","volume":"83","author":"Keats","year":"2023","journal-title":"Cancer Res."},{"issue":"25","key":"2026072715454438100_cit25","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired Resistance to KRASG12C Inhibition\nin Cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"2026072715454438100_cit26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced Protein Degradation: An Emerging\nDrug Discovery\nParadigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"3","key":"2026072715454438100_cit27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC\nTargeted Protein Degraders:\nThe Past Is Prologue","volume":"21","author":"Be\u0301ke\u0301s","year":"2022","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"2","key":"2026072715454438100_cit28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS Inhibitors: Resistance\nDrivers and Combinatorial Strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends\nCancer"},{"issue":"Suppl_16","key":"2026072715454438100_cit29","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1200\/jco.2024.42.16_suppl.5011","article-title":"ARV-766, a Proteolysis\nTargeting\nChimera (PROTAC) Androgen Receptor (AR) Degrader, in Metastatic Castration-Resistant\nProstate Cancer (mCRPC): Initial Results of a Phase 1\/2 Study","volume":"42","author":"Petrylak","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"2026072715454438100_cit30","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1021\/acs.jmedchem.4c00107","article-title":"Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs\nTargeting C797S Mutation","volume":"67","author":"Zhu","year":"2024","journal-title":"J. Med. Chem."},{"key":"2026072715454438100_cit31","article-title":"Preclinical\nEvaluation of CFT8919 as a Mutant Selective Degrader of EGFR with\nL858R Activating Mutations for the Treatment of Non-Small Cell Lung\nCancer","author":"Park"},{"issue":"4","key":"2026072715454438100_cit32","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1021\/acs.jmedchem.3c01007","article-title":"Discovery and Preclinical\nPharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton\u2019s\nTyrosine Kinase with Immunomodulatory Activity for the Treatment of\nPatients with B Cell Malignancies","volume":"67","author":"Robbins","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026072715454438100_cit33","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted\nDegradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Central Sci."},{"issue":"2","key":"2026072715454438100_cit34","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, Synthesis,\nand Biological Evaluation of Potent and Selective PROTAC Degraders\nof Oncogenic KRASG12D","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6715","key":"2026072715454438100_cit35","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting Cancer with\nSmall-Molecule Pan-KRAS Degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"Suppl_4","key":"2026072715454438100_cit36","doi-asserted-by":"publisher","first-page":"TPS764","DOI":"10.1200\/jco.2023.41.4_suppl.tps764","article-title":"Trial in Progress:\nA Phase 1, First-in-Human,\nOpen-Label, Multicenter, Dose-Escalation and Dose-Expansion Study\nof ASP3082 in Patients with Previously Treated Advanced Solid Tumors\nand KRAS G12D Mutations","volume":"41","author":"Tolcher","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2026072715454438100_cit37","unstructured":"Sun, W.; Ye, J.; Deng, T.; Wang, L.; Guo, L.; Zhao, S.; Zhai, W.; Liu, D.\n          KRAS-PROTAC Chimeric\nCompound and Use Thereof. WO 2025061079 A1, 2025."},{"key":"2026072715454438100_cit38","unstructured":"Zhang, C.; He, P.; Huang, Q.; Qin, L.; Liao, P.; Li, Y.; Yan, P.\n          Compound\nCapable of Degrading KRAS and Application of Compound in Medicine. CN119219669A, 2024."},{"key":"2026072715454438100_cit39","unstructured":"Sun, Y.; Fu, J.; Zeng, H.\n          Bifunctional Compounds for Degrading\nKRAS G12D via Ubiquitin Proteasome Pathway. WO 2024050742\nA1, 2024."},{"issue":"10","key":"2026072715454438100_cit40","doi-asserted-by":"publisher","first-page":"10238","DOI":"10.1021\/acs.jmedchem.5c00428","article-title":"Discovery and Characterization\nof\nRP03707: A Highly Potent and Selective KRASG12D PROTAC","volume":"68","author":"Ji","year":"2025","journal-title":"J. Med. Chem."},{"issue":"13","key":"2026072715454438100_cit41","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis Targeting\nChimeras (PROTACs)\nin \u2018beyond Rule-of-Five\u2019 Chemical Space: Recent Progress\nand Future Challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"2026072715454438100_cit42","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","article-title":"Discovery\nof the First-in-Class Agonist-Based\nSOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS\nMutations","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026072715454438100_cit43","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-Targeting\nChimeras with Reduced off-Targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c01034","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/19\/20103\/66291298\/acs.jmedchem.5c01034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/19\/20103\/66291298\/acs.jmedchem.5c01034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:53:33Z","timestamp":1785182013000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/19\/20103\/5234618\/ZJK-807-A-Selective-PROTAC-Degrader-of-KRASG12D"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":43,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,9,25]]},"published-print":{"date-parts":[[2025,10,9]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01034","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]}}}